SCHEMBL2484809

SCHEMBL2484809

C=CCN(CC=C)C(O)C(C)O

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8945620 0.80 MEN1 (0.30) MEN1KMT2A
SCHEMBL787268 0.79 MEN1 (0.32) MEN1KMT2A
SCHEMBL28133084 0.78
Bromide SCHEMBL11042423 0.77 MEN1 (0.31) MEN1KMT2A
Hydrochloric Acid SCHEMBL7975590 0.77 MEN1 (0.31) MEN1KMT2A
SCHEMBL8945835 0.76
SCHEMBL321521 0.73
SCHEMBL1137481 0.73 MEN1 (0.33) MEN1KMT2A
SCHEMBL5267872 0.72
SCHEMBL23475212 0.71 MEN1 (0.32) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268015-B2 Method for decolorizing keratin-containing fibers HENKEL AG & CO. KGAA (DE) 2012-09-18 US disclosed
US-20120114831-A1 HIGH EFFICIENCY ENCAPSULATION OF CHARGED THERAPEUTIC AGENTS IN LIPID VESICLES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2012-05-10 US disclosed
US-20110247644-A1 Method for Decolorizing Keratin-Containing Fibers HENKEL AG & CO. KGAA (DE) 2011-10-13 US disclosed
US-8021686-B2 Lipid-encapsulated polyanionic nucleic acid THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-09-20 US disclosed
EP-2113247-A2 High efficiency encapsulation of nucleic acids in lipid vesicles THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2009-11-04 EP disclosed
EP-1027033-B1 HIGH EFFICIENCY ENCAPSULATION OF NUCLEIC ACIDS IN LIPID VESICLES UNIV BRITISH COLUMBIA (CA) 2009-07-22 EP disclosed
US-20080200417-A1 HIGH EFFICIENCY ENCAPSULATION OF CHARGED THERAPEUTIC AGENTS IN LIPID VESICLES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2008-08-21 US disclosed
US-20080152604-A1 SKIN-LIGHTENING COMPOSITIONS WITH AN IMPROVED ACTION HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2008-06-26 US disclosed
US-7341738-B2 Lipid-encapsulated polyanionic nucleic acid THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2008-03-11 US disclosed
US-20050255153-A1 Mixture of deprotonatable lipid, such as polyoxyethylene glycol or polyamide lipid with buffered aqueous solution of charged drug INEX PHARMACEUTICALS CORP. (CA) 2005-11-17 US disclosed
US-6858225-B2 Lipid-encapsulated polyanionic nucleic acid INEX PHARMACEUTICALS CORPORATION (CA) 2005-02-22 US disclosed
US-20050008689-A1 High efficiency encapsulation of charged therapeutic agents in lipid vesicles INEX PHARMACEUTICALS CORPORATION 2005-01-13 US disclosed
US-20030129221-A1 High efficiency encapsulation of charged therapeutic agents in lipid vesicles SEMPLE SEAN C (CA) 2003-07-10 US disclosed
US-20020147121-A1 Methods of enhancing cleaning compositions by combining alk(en)yl oligoglycosided and hydroxycarboxylic acid partial esters COGNIS DEUTSCHLAND GMBH & CO. KG (DE) 2002-10-10 US disclosed
US-6287591-B1 STABLE FOR THERAPUTIC USE, HIV, CYTOMEGALO VIRUS, ANTIINFLAMMATORY, ANTITUMOR INEX PHARMACEUTICALS CORP. (CA) 2001-09-11 US disclosed
EP-1027033-A2 HIGH EFFICIENCY ENCAPSULATION OF CHARGED THERAPEUTIC AGENTS IN LIPID VESICLES Inex Pharmaceuticals Corp. (CA) 2000-08-16 EP disclosed
WO-1998051278-A2 HIGH EFFICIENCY ENCAPSULATION OF CHARGED THERAPEUTIC AGENTS IN LIPID VESICLES INEX PHARMACEUTICALS CORPORATION (CA) 1998-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050008689-A1 High efficiency encapsulation of charged therapeutic agents in lipid vesicles PHOSPHO1, LIPA, CHMP4B MEN1 2561/4885KMT2A 971/4885
US-20110247644-A1 Method for Decolorizing Keratin-Containing Fibers KRT18, PLOD3, DSG1 MEN1 4660/4885KMT2A 228/4885
US-20080200417-A1 HIGH EFFICIENCY ENCAPSULATION OF CHARGED THERAPEUTIC AGENTS IN LIPID VESICLES PHOSPHO1, LIPA, CHMP4B MEN1 2561/4885KMT2A 971/4885
US-20050255153-A1 Mixture of deprotonatable lipid, such as polyoxyethylene glycol or polyamide lipid with buffered aqueous solution of charged drug PHOSPHO1, LIPA, CHMP4B MEN1 2151/4885KMT2A 580/4885
US-20030129221-A1 High efficiency encapsulation of charged therapeutic agents in lipid vesicles PHOSPHO1, LIPA, CHMP4B MEN1 2561/4885KMT2A 971/4885
US-20080152604-A1 SKIN-LIGHTENING COMPOSITIONS WITH AN IMPROVED ACTION ALAD, TYR, CYP24A1 MEN1 1792/4885KMT2A 4039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.